Centralized Review
How Centralized IBC Review Can Benefit Gene Therapy Research
Understand the risks and regulatory requirements for gene therapy research and how a biosafety review can benefit this type of research.
Local Versus Central IRBs: What’s the Difference?
Local IRBs and central IRBs are not really that different, although sIRB mandates have complicated things for local IRBs.
Virtual Symposium: Gene Therapy Research in the Age of COVID-19
The coronavirus pandemic has brought genetic research to the forefront. To address emerging issues, Advarra presents its first virtual symposium. Read more:
Keep in Touch: Tips for Working with a Single IRB for the First Time
Recent regulations and policies have many institutions establishing policies and processes for working with an external sIRB. Read more:
How Sites Can Prepare for COVID-19 Genetically Engineered Vaccine Studies
Is your site prepared to participate in COVID-19 vaccine research? Registering an IBC ahead of time gives you an advantage. Read more:
A Tale of Two Sites: The Power of Integrated Research Administration
Learn how institutions attract more studies from the the tale of two sites: one with an integrated research administration, and one without.
Reporting to the IRB: Unanticipated Device Effects (UADEs) in Medical Device Studies
What do the regulations say about unanticipated device effects and IRB reporting requirements? In this blog, Advarra addresses some frustrating gray areas.
Subscribe to our monthly email
Receive updates monthly about webinars for CEUs, white papers, podcasts, and more.
Advancing Clinical Research: Safer, Smarter, Faster™
Copyright © 2023 Advarra. All Rights Reserved.